Citations

Clear

7 citation(s) found for "Chen, Amy".

Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States
Garrett, Giorgia L., Boscardin, John, Lloyd, Amanda Abramson, Ahmed, Rehana L. , Anthony, Tiffany, Bibee, Kristin , Breithaupt, Andrew, Cannon, Jennifer, Chen, Amy , Cheng, J , Fuxench, Zelma C. Chiesa , Colegio, Oscar R. , Curiel‐Lewandrowski, Clara , Guzzo, Christina A. Del, Disse, Max, Dowd, Margaret , Eilers, Robert, Ortiz, Arisa , Golden, Spring, Graves, Michael S., Griffin, John R., Hopkins, R. Samuel, Huang, Conway C. , Jambusaria, Anokhi, Jennings, Thomas , Khetarpal, Shilpi , Kim, Chang-Hyun , Klintmalm, Göran B. , Konicke, Kathryn, Koyfman, Shlomo A. , Lam, Charlene , Leitenberger, Justin J. , Loh, Tiffany Y. , Lowenstein, Stefan E. , Madankumar, Reshmi, Moreau, Jacqueline F. , Nijhawan, Rajiv I. , Ochoa, Shari A. , Olasz, Edit , Otchere, Elaine , Otley, Clark C. , Oulton, Jeremy, Patel, Parth H., Prabhu, Arpan V. , Pugliano‐Mauro, Melissa , Schmults, Chrysalyne D. , Schram, Sarah E., Shih, Allen F. , Shin, Thuzar M. , Soon, Seaver L. , Stein, Jennifer , Sternhell‐Blackwell, Kara, Taylor, Stan, Vidimos, Allison T. , Wu, Peggy A. , Zajdel, Nicholas, Zelac, Daniel E. , Arron, Sarah T. , Kim, Changhyun, Ochoa, Shari, Otley, Clark, Blanc, Paul David , Boscardin, W. John , Morris, Caroline Rose , Bae, Gordon Hyeonjin , Jambusaria‐Pahlajani, Anokhi , Jiang, Shang I. Brian , Karia, Pritesh S. , Lee, Peter, Patel, Vishal Anil , Soriano, Teresa T. , Srivastava, Divya , Nj, Zajdel

Mayo Clinic

JAMA Dermatology | January 17, 2017 | Volume: 153 | Issue: 3 | Pages: 296

10.1001/jamadermatol.2016.4920 | PMID 28097368 Get It

American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making
Bernet, Victor , Chen, Amy , Fahey, Thomas J. , Ganly, Ian , Hodak, Steven P., Kebebew, Electron , Patel, Kepal N. , Shaha, Ashok R. , Steward, David L. , Wiseman, Sam M. , Carty, Sally E. , Ferris, Robert L. , Baloch, Zubair , Tufano, Ralph Patrick

Mayo Clinic

Thyroid® | June 10, 2015 | Volume: 25 | Issue: 7 | Pages: 760-768

10.1089/thy.2014.0502 | PMID 26058403 Get It

Background: Recent advances in research on thyroid carcinogenesis have yielded applications of diagnostic molecular biomarkers and profiling panels in the management of thyroid nodules. The specific utility of these novel, clinically available molecular tests is becoming widely appreciated, especially in perioperative decision making by the surgeon regarding the need for surgery and the extent of initial resection. Methods: A task force was convened by the Surgical Affairs Committee of the American Thyroid Association and was charged with writing this article. Results/Conclusions: This review covers the clinical scenarios by cytologic category for which the thyroid surgeon may find molecular profiling results useful, particularly for cases with indeterminate fine-needle aspiration cytology. Distinct strengths of each ancillary test are highlighted to convey the current status of this evolving field, which has already demonstrated the potential to streamline decision making and reduce unnecessary surgery, with the accompanying benefits. However, the performance of any diagnostic test, that is, its positive predictive value and negative predictive value, are exquisitely influenced by the prevalence of cancer in that cytologic category, which is known to vary widely at different medical centers. Thus, it is crucial for the clinician to know the prevalence of malignancy within each indeterminate cytologic category, at one's own institution . Without this information, the performance of the diagnostic tests discussed below may vary substantially.
American Thyroid Association Statement on Optimal Surgical Management of Goiter
Chen, Amy Y. , Bernet, Victor , Carty, Sally E. , Ganly, Ian , Inabnet, William B. , Shaha, Ashok R. , Davies, Terry F.

Mayo Clinic

Thyroid® | December 3, 2013 | Volume: 24 | Issue: 2 | Pages: 181-189

10.1089/thy.2013.0291 | PMID 24295043 Get It

Background: Goiter, or benign enlargement of the thyroid gland, can be asymptomatic or can cause compression of surrounding structures such as the esophagus and/or trachea. The options for medical treatment of euthyroid goiter are short-lived and are limited to thyroxine hormone suppression and radioactive iodine ablation. The objective of this statement article is to discuss optimal surgical management of goiter. Methods: A task force was convened by the Surgical Affairs Committee of the American Thyroid Association and was tasked with writing of this article. Results/Conclusions: Surgical management is recommended for goiters with compressive symptoms. Symptoms of dyspnea, orthopnea, and dysphagia are more commonly associated with thyromegaly, in particular, substernal goiters. Several studies have demonstrated improved breathing and swallowing outcomes after thyroidectomy. With careful preoperative testing and thoughtful consideration of the type of anesthesia, including the type of intubation, preparation for surgery can be optimized. In addition, planning the extent of surgery and postoperative care are necessary to achieve optimal results. Close collaboration of an experienced surgical and anesthesia team is essential for induction and reversal of anesthesia. In addition, this team must be cognizant of complications from massive goiter surgery such as bleeding, airway distress, recurrent laryngeal nerve injury, and transient hypoparathyroidism. With careful preparation and teamwork, successful thyroid surgery can be achieved.
Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction
Baran, Kenneth W., Nguyen, Michel, McKendall, George R., Lambrew, Costas T., Dykstra, Gary, Palmeri, Sebastian T., Borzak, Steven, Sobel, Burton E., Gourlay, Steven G. , Rundle, Amy Chen, Barron, Hal V., Gibbons, Raymond J. , Gibson, C. Michael

Mayo Clinic

Circulation | September 28, 2007 | Volume: 104 | Issue: 23 | Pages: 2778-2783

10.1161/hc4801.100236 | PMID 11733394 Get It

Background Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the β2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent. Methods and Results The Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction Study (LIMIT AMI) was a randomized, double-blind, placebo-controlled, multicenter study conducted in 60 centers in the United States and Canada. A total of 394 subjects who presented within 12 hours of symptom onset with ECG findings (ST-segment elevation) consistent with AMI were treated with recombinant tissue plasminogen activator and were also given an intravenous bolus of 0.5 or 2.0 mg/kg rhuMAb CD18 or placebo. Coronary angiography was performed at 90 minutes, 12-lead ECGs were obtained at baseline, 90, and 180 minutes, and resting sestamibi scans were performed at ≥120 hours. Adjunctive angioplasty and use of glycoprotein IIb/IIIa antiplatelet agents at the time of angiography were discretionary. There were no treatment effects on coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution, despite the expected induction of peripheral leukocytosis. A slight trend toward an increase in bacterial infections was observed with rhuMAb CD18 ( P =0.33). Conclusions RhuMAb CD18 was well tolerated but not effective in modifying cardiac end points.
TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association With Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging
Angeja, Brad G., Gunda, Madhavi, Sobel, Burton E., Rundle, Amy Chen, Syed, Mushabbar , Asfour, Abdelrahim, Borzak, Steven, Gourlay, Steven G. , Barron, Hal V., Murphy, Sabina A. , Gibbons, Raymond J. , Gibson, C. Michael

Mayo Clinic

Circulation | July 28, 2002 | Volume: 105 | Issue: 3 | Pages: 282-285

10.1161/hc0302.103588 | PMID 11804979 Get It

Background — The TIMI myocardial perfusion grade (TMPG) and ST-segment resolution both reflect perfusion and are associated with mortality after thrombolysis for acute myocardial infarction. We hypothesized that these measures would also be associated with infarct size by single photon emission computed tomography (SPECT). Methods and Results — In the LIMIT AMI trial (Limitation of Myocardial Injury following Thrombolysis in Acute Myocardial Infarction) of lytic monotherapy versus lytic plus rhuMAb CD18, early 90-minute TMPG (n=221) and ST segment resolution (n=242) were compared with subsequent SPECT Technetium-99 m Sestamibi, measuring the percentage of the left ventricle with no Sestamibi uptake. Infarct sizes were larger with TMPG 0 or 1 (a closed or stained myocardium) than with TMPG 2 or 3 (open myocardium, median 13% versus 7%, P =0.004). Infarcts were also larger in patients with no ST segment resolution (median 15%) or incomplete resolution (11%) than in those with complete resolution (6%, overall P =0.0001). The difference in infarct size by TMPG persisted when stratified by category of ST resolution. Conclusions — There may be a pathophysiological link between early restoration of tissue-level perfusion and reduced subsequent infarct size that may partially explain why these early angiographic and electrocardiographic measures are associated with long-term survival.